Back to search results

Understanding Recovery from COVID-19

This study aims to understand how people recover from COVID-19. Researchers will collect information through surveys and interviews to describe the different ways people experience and recover from the illness. They want to learn about the range and timing of symptoms before, during, and after COVID-19 infection. This information will help design future studies to understand why some people don't fully recover. You can join if you are 18 or older and have documentation of a positive COVID-19 or antibody test. The study is currently unclear on its recruitment status.

Study design
This is an observational study planning to enroll 1590 participants. It uses surveys and interviews to gather information.
What's involved
You will be screened with a 15-minute telephone interview and provide your COVID-19 test results and medical records. You will also participate in telephone interviews and internet-based questionnaires.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints are measured at the End of Study for the Screening Phase, Phase C: Deep Phenotyping, and Phase B: Evaluation. Participants are required to be within the first five years of their recovery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04573062

Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

Recruiting
Not specifiedAges 18+Observational
National Institute of Neurological Disorders and Stroke (NINDS)
~1,590 participants
Updated 2026-08-24 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Screening Phase
Measured over End of Study
+2 more outcomes measured

Conditions

Post-Coronavirus Disease 19

Explore related trials

COVID-19 InfectionPost-COVID-19COVID-19 Infection

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Brian T Walitt, M.D. · PRINCIPAL_INVESTIGATOR · National Institute of Neurological Disorders and Stroke (NINDS)

Who to contact

Cynthia L Vierria
[email protected]
(301) 594-6760
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinical or radiographic evidence of pneumonia, OR
Acute respiratory distress syndrome (ARDS).
The date that fever broke for the first time
The date the participant recalls starting to improve
If a participant is unable to report a reliable date, a date of six weeks from the onset of COVID-19 symptoms may be imputed. 9. Does not have an active SARS-CoV-2 infection. The protocol will conform with NIH CC standards for documenting a participant does not have active SARS-CoV- 2 infection. This may include screening interviews and/or testing.
2: Ambulatory; symptomatic, independent
3: Ambulatory; symptomatic, assistance needed
4: Hospitalized; no oxygen therapy
5: Hospitalized; oxygen by mask or nasal prongs
6: Hospitalized; oxygen by non-invasive ventilation or high flow oxygen 5. Functional Criteria: Substantial symptom severity as determined using SF-36v2: score of \<=70 physical function subscale, or \<=50 on role physical subscale, or \<=75 on social function subscale.
2: Ambulatory; symptomatic, independent
3: Ambulatory; symptomatic, assistance needed
4: Hospitalized; no oxygen therapy
5: Hospitalized; oxygen by mask or nasal prongs
6: Hospitalized; oxygen by non-invasive ventilation or high flow oxygen
2: Ambulatory; symptomatic, independent
3: Ambulatory; symptomatic, assistance needed
4: Hospitalized; no oxygen therapy
5: Hospitalized; oxygen by mask or nasal prongs
6: Hospitalized; oxygen by non-invasive ventilation or high flow oxygen 5. Functional Criteria: Mild to moderate symptom severity as determined using SF-36v2: score of between 71 and 84 on the physical function subscale, or between 51 and 84 on role physical subscale, or between 76 and 84 on social function subscale.

What this trial measures

  • Screening PhaseEnd of Study

    The number and severity of persistent symptoms associated with COVID-19 convalescence. Collected data will be used to characterize different narratives of COVID-19 convalescence.

  • Phase C: Deep PhenotypingEnd of Study

    Phase C: Immune system and inflammatory signaling characterization in at baseline and following maximal exercise exertion using flow cytometry, RNA sequencing, multiplex immunochemical analysis, NK cell functional analysis. Microbiome characterization at baseline and following maximal exercise exertion using shotgun metagenomics. Bioenergetics, autonomic, and metabolic characterization using mitochondrial plasmid genotyping, pulmonary spirometry, gas exchange measurements during exercise, metabolic chamber measurements of total body energy use, metabolomic analysis of stool, mitochondrion proteomics and metabolomics from muscle, and functional respiration of PBMCs using extracellular flux mito stress assay.

  • Phase B: EvaluationEnd of Study

    Phase B: Standard clinical and research evaluations will be used to measure cardiopulmonary, neurological, and functional status and identify individuals with unknown PASC.